BioWorld Asia

Oct. 5, 2011

Creabilis Raises $20M in Series B to Advance Psoriasis Drug

Creabilis S.A. raised €15 million (US$20 million) in a Series B round to advance a pipeline of three compounds in development for dermatology, inflammation and pain indications. (BioWorld International) Read More

European Biomedical Research Lags U.S. in Quality, Spending

Proposed Leukemia Therapy Acts Through Epigenetics

Galapagos Bags Potential $346M Cancer R&D Deal with Servier

Prosonix Brings in £11.4M to Back Smart Particle Technology

Lundbeck Gets Dibs on Proximagen CNS Products

$54M EC Vaccine Research Initiative to Kick Off in Siena

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...